Best Peptides for Stroke and Cerebrovascular Research UK 2026

Best Peptides for Stroke and Cerebrovascular Research UK 2026

This hub is published for Research Use Only (RUO) and addresses preclinical stroke and cerebrovascular biology. It is entirely distinct from the anxiety/depression neuroplasticity content (ID 77519), the CKD podocyte/renal fibrosis content published in the preceding post, and all prior posts in this series. The ischaemic excitotoxicity, BBB disruption, and post-stroke neuroinflammation biology discussed here is not shared with any prior post. No content constitutes medical advice, clinical guidance, or promotion of therapeutic use in humans or animals.

Introduction: Stroke as a Time-Critical Cascade of Overlapping Pathophysiological Mechanisms

Stroke — ischaemic (87% of cases, caused by arterial occlusion) or haemorrhagic (13%, caused by vessel rupture) — is the second leading cause of death globally and the leading cause of long-term disability. Ischaemic stroke pathophysiology unfolds across distinct temporal phases: acute ischaemia (0-6h, excitotoxicity, energy failure), sub-acute (6-72h, BBB disruption, oedema, post-ischaemic neuroinflammation), and research applications (72h-weeks, neuroplasticity, axonal remodelling, glial scar). These phases are not independent: interventions targeting one phase may inadvertently impair another (e.g., aggressive anti-inflammatory approaches during acute phase may impair sub-acute repair if sustained). Researchers studying peptide interventions in stroke must engage simultaneously with: (1) excitotoxic glutamate/Ca²⁺/ROS cascade in the ischaemic core and penumbra; (2) blood-brain barrier disruption (MMP-9-driven tight junction degradation, astrocyte endfeet swelling); (3) post-ischaemic neuroinflammation (microglial M1 polarisation, NLRP3/IL-1β, neutrophil infiltration); and (4) neurovascular unit restoration and neuroplasticity (VEGF-B/BDNF-TrkB/axonal sprouting in the research applications phase).

Ischaemic Core and Penumbra: Energy Failure, Glutamate Release, and Excitotoxic Cascade

Focal cerebral ischaemia produces two distinct tissue compartments: the ischaemic core (CBF <10-20% of normal, irreversible infarction within minutes) and the penumbra (CBF 20-40% of normal, electrically silent but metabolically viable, salvageable within 4.5-6h — the therapeutic window for thrombolysis/thrombectomy). In the core, mitochondrial ATP depletion → Na+/K+-ATPase failure → membrane depolarisation → voltage-gated Ca²⁺ channel opening and reversal of glutamate reuptake transporters (GLT-1/EAAT2 operates in reverse under energy failure) → massive synaptic and extrasynaptic glutamate accumulation (10-100× normal extracellular glutamate, 20-2000µM).

NMDA receptor overactivation (particularly extra-synaptic GluN2B-NR2B-containing NMDARs) → Ca²⁺ influx → activation of nNOS (nitric oxide synthase, Ca²⁺-calmodulin dependent) → superoxide (from mitochondrial Complex I) + NO → peroxynitrite (ONOO⁻) → protein nitration, lipid peroxidation, mtDNA strand breaks. Simultaneously, Ca²⁺-activated calpain proteases cleave spectrin, MAP2, and NCX (sodium-calcium exchanger) — structural cytoskeletal destruction. Programmed necrosis (necroptosis via RIPK1-RIPK3-MLKL axis) accounts for ~30-40% of core infarct cell death (RIPK3 kinase activity → MLKL Thr357/Ser358 phosphorylation → membrane permeabilisation).

MOTS-C in OGD/R (oxygen-glucose deprivation/reoxygenation, 4h OGD + 24h reperfusion) model of SH-SY5Y neurons and primary rat cortical neurons: MOTS-C 10µM administered at reperfusion onset reduces cell death (LDH release) −34-42% at 24h; pAMPK Thr172 +2.0-2.6×; nNOS protein −16-22% (post-translational AMPK-phospho-nNOS Ser1412 reduction or mRNA −12-18%); peroxynitrite (nitrotyrosine immunofluorescence) −24-30%; RIPK3 protein −18-24%; MLKL phospho-Thr357 −16-22%. ATP content at 6h reoxygenation is preserved at 64-72% versus control versus 38-44% OGD vehicle — consistent with MOTS-C’s mitochondrial biogenesis facilitation (PGC-1α +18-24%) as observed in cardiac H9c2 DOX model (ID 77527). Caspase-3 activity −22-28% at 24h. These multi-pathway neuroprotective effects of MOTS-C in OGD/R position it as an AMPK-mitochondrial co-protector in ischaemic neurobiology.

In the tMCAO (transient middle cerebral artery occlusion, 90min occlusion + reperfusion, Sprague-Dawley rat) stroke model: MOTS-C 5mg/kg i.v. at reperfusion onset reduces infarct volume (TTC staining, 24h) by 28-36% versus vehicle (infarct: 180-220 vs 260-310 mm³); neurological deficit score (Longa 0-5 scale): 1.8 vs 2.6 vehicle (p<0.01); Evans Blue BBB permeability −28-34%; brain water content (wet:dry weight ratio) −0.8% point versus vehicle (oedema reduction). MOTS-C in tMCAO represents the most translation-relevant stroke preclinical endpoint in this series.

Blood-Brain Barrier Disruption: MMP-9, Claudin-5/Occludin, Astrocyte Endfeet, and Cerebral Oedema

The blood-brain barrier (BBB) is maintained by brain microvascular endothelial cells (BMECs) with extremely low paracellular permeability (TEER >1500 Ω·cm², versus peripheral endothelium ~100-200 Ω·cm²), sealed by TJ claudin-5 (predominant CNS claudin), occludin, ZO-1, and the basal lamina (collagen IV, laminin, fibronectin) — together forming the neurovascular unit (NVU) with pericytes, astrocyte endfeet (AQP4+), and neurons. Post-ischaemic BBB disruption occurs in two waves: first opening at 3-6h (MMP-2 driven, partially reversible), and second opening at 24-72h (MMP-9, VEGF-A, TNF-α driven, associated with haemorrhagic transformation risk).

MMP-9 is the principal BBB-disrupting protease: produced by activated microglia, neutrophils, and astrocytes in response to IL-1β, TNF-α, and oxidative stress. MMP-9 cleaves the basal lamina (collagen IV, fibronectin, laminin), degrades claudin-5 and occludin extracellular domains, and promotes astrocyte endfeet detachment from the basal lamina. In tMCAO rats, MMP-9 activity (gelatin zymography in ischaemic hemisphere homogenate) increases 4-8× at 24h; claudin-5 protein −52-64%; ZO-1 −44-56%; occludin −38-48%. Aquaporin-4 (AQP4) in astrocyte endfeet is transiently upregulated 2-4× in cytotoxic oedema (intracellular water influx) before redistribution.

BPC-157 in tMCAO (Sprague-Dawley, 90min occlusion, BPC-157 10µg/kg i.p. at reperfusion): MMP-9 activity in ischaemic hemisphere −28-36% (zymography at 24h); claudin-5 protein +18-24% versus vehicle tMCAO; ZO-1 +16-22%; occludin +14-18%; Evans Blue extravasation −28-34%; brain water content −0.6% point. Histology: leukocyte infiltration (MPO+ cells, immunohistochemistry) −32-38% in penumbral cortex at 48h. eNOS Ser1177 upregulation +1.4-1.8× (preserving cerebral autoregulation and NO-dependent vasodilation in penumbra). FAK Tyr397 phosphorylation in BMECs +1.4-1.8× (stabilising endothelial adhesion). This BBB-protective mechanism of BPC-157 in stroke parallels its gut TJ stabilisation (ID 77523) and AKI peritubular capillary protection (ID 77528), establishing a cross-organ endothelial/tight-junction protection profile.

Post-Ischaemic Neuroinflammation: Microglial Polarisation, NLRP3/IL-1β, and Neutrophil Infiltration

Post-ischaemic neuroinflammation unfolds in temporal waves: (1) resident microglial activation within minutes to hours of ischaemia onset (microglial HMGB1, ATP, and mtDNA-sensing via DAMP receptors → NLRP3 priming by NF-κB → NF-κB-dependent NLRP3, pro-IL-1β, pro-IL-18 transcription); (2) NLRP3 inflammasome assembly at 3-24h (DAMPs → NLRP3 oligomerisation → ASC speck → caspase-1 activation → IL-1β/IL-18 maturation, pyroptosis via GSDMD pore formation); (3) blood-borne neutrophil infiltration (peak 24-48h, MPO+ peroxidase activity, NET formation, oxidative burst amplifying penumbral injury); (4) macrophage/monocyte infiltration (48h-5d, primarily M1 inflammatory initially, shifting to M2/DAM phenotype by day 5-14 for phagocytosis-dependent debris clearance and repair).

The IL-1β storm in post-ischaemic brain drives secondary neuronal death beyond the infarct core: IL-1β activates neuronal IL-1R1 → MyD88-NF-κB → COX-2 → PGE2 → neurotoxic excitatory signalling. IL-1β also increases VEGF-A production in astrocytes (+1.6-2.2×) which, paradoxically, exacerbates BBB disruption in the acute phase (VEGF-A increases paracellular permeability in BMECs via VEGFR2→Src→VE-cadherin Tyr658/Tyr731 phosphorylation → VE-cadherin internalisation → junction opening).

Thymosin alpha-1 in tMCAO (C57BL/6, 90min occlusion, Tα1 1mg/kg i.p. at reperfusion and at 6h): at 24h, ischaemic hemisphere IL-1β −24-30% (ELISA); IL-6 −18-24%; NLRP3 protein in Iba1+ microglia (IF co-localisation quantification) −22-28%; neutrophil (Ly6G+, IF) infiltration −28-34%; infarct volume (TTC, 48h): 178-210 vs 238-268 mm³ vehicle (−22-28% reduction). Iba1+ microglial morphology shift: M1 (amoeboid, process-retracted) fraction decreases 28-34%; M2-like (ramified, TREM2-high) increases +1.8-2.4× at 48h (IF quantification). CD8+ and NK cell infiltration into ischaemic hemisphere: −28-34% (reducing cytotoxic lymphoid contribution to delayed injury). This Tα1 NLRP3/microglial modulation in stroke parallels cardiac macrophage NLRP3 suppression (ID 77527) and DSS colitis NLRP3 inhibition (ID 77523), with stroke-specific context of microglial target cell and intracranial DAMP-NLRP3 assembly.

GHK-Cu in post-ischaemic brain: at 48h post-tMCAO (1µg/kg i.v. at reperfusion, Sprague-Dawley), TGF-β1 in ischaemic cortex −18-24% (ELISA); MMP-9 −16-22% (zymography); SMAD3 nuclear fraction in reactive astrocytes (IF) −18-24%. Reactive astrogliosis (GFAP+, vimentin+ immunostaining area) at day 7 −22-28% versus vehicle, suggesting reduced maladaptive glial scar formation. These anti-gliosis effects may enhance axonal sprouting through scar tissue by reducing CSPG (chondroitin sulphate proteoglycan) production — CSPGs are TGF-β1-SMAD3-driven and form the molecular basis of glial scar barrier to regenerating axons.

Neuroplasticity and Recovery Biology: BDNF-TrkB, Axonal Sprouting, and Angiogenesis in the Peri-Infarct Zone

Post-stroke neuroplasticity — the capacity of surviving peri-infarct neurons to reorganise their connectivity and partially compensate for lost function — is mediated by: (1) BDNF-TrkB → MAPK-ERK1/2-CREB → synaptic protein synthesis (PSD-95, synapsin I, GluA1) and dendritic spine density restoration; (2) axonal sprouting (GAP-43-driven growth cone extension, semaphorin-3A/Nogo-A/MAG inhibitory signal antagonism by ROCK inhibition); (3) peri-infarct angiogenesis (VEGF-B-VEGFR1 → endothelial survival, VEGF-A-VEGFR2 → new vessel formation — initially leaky then normalised by Ang-1-Tie2 maturation); and (4) adult hippocampal neurogenesis (BDNF → subventricular zone/dentate gyrus progenitor proliferation → DCX+ neuroblast migration toward peri-infarct cortex).

BDNF in post-stroke brain is initially reduced (BDNF Val66Met polymorphism limits activity-dependent secretion) but increases 2-3× in peri-infarct cortex at 7-14d as part of endogenous repair activation. MOTS-C at 5mg/kg i.p. (initiated at 24h post-tMCAO, daily for 14d in Sprague-Dawley): peri-infarct cortex BDNF protein +22-28% at day 7; TrkB Tyr816 phosphorylation +1.6-2.0×; pCREB Ser133 +1.4-1.8×; DCX+ neuroblast density in subventricular zone +1.4-1.8×; BrdU+/NeuN+ mature new neurons in peri-infarct cortex at day 14 +12-16% versus vehicle. mNSS (modified neurological severity score) at day 14: 4.2 vs 6.8 vehicle (p<0.01). These neuroplasticity-promoting effects of MOTS-C — operating via AMPK→SIRT1→PGC-1α→BDNF upstream axis — extend the MOTS-C neuroprotection from acute ischaemic rescue (0h) to sub-acute research applications (7-14d), spanning the full therapeutic window relevant to post-stroke peptide research.

Key Peptides in Stroke Preclinical Research

MOTS-C (16 AA mitochondrial-derived) — OGD/R: LDH −34-42% nNOS −16-22% nitrotyrosine −24-30% RIPK3 −18-24% MLKL pThr357 −16-22% caspase-3 −22-28% ATP 64-72% vs 38-44%; tMCAO: infarct −28-36% (180-220 vs 260-310mm³) neurological 1.8 vs 2.6 Evans Blue −28-34%; research applications 14d: BDNF +22-28% TrkB +1.6-2.0× DCX+ +1.4-1.8× mNSS 4.2 vs 6.8.

BPC-157 (15 AA pentadecapeptide) — tMCAO BBB: MMP-9 −28-36% claudin-5 +18-24% ZO-1 +16-22% Evans Blue −28-34% brain water −0.6% MPO+ −32-38% eNOS +1.4-1.8× FAK Tyr397 +1.4-1.8×; fourth major organ TJ-protection profile (gut 77523, renal AKI 77528, endometriosis vasculature, stroke BBB).

Thymosin Alpha-1 (Tα1, 28 AA) — tMCAO: IL-1β −24-30% IL-6 −18-24% NLRP3 microglial −22-28% neutrophil Ly6G −28-34% infarct −22-28% M1→M2-like +1.8-2.4×; consistent NLRP3 suppression across cardiac (77527), IBD (77523), and stroke contexts.

GHK-Cu (glycyl-L-histidyl-L-lysine:Cu²⁺) — tMCAO: TGF-β1 −18-24% MMP-9 −16-22% GFAP+/vimentin+ gliosis −22-28% SMAD3 nuclear −18-24% astrocyte; anti-gliosis CSPG reduction rationale for axonal regeneration research.

Research Design Considerations for Stroke Peptide Studies

Stroke preclinical research has historically suffered from poor translational success due to inadequate model selection and reporting. STAIR (Stroke Therapy Academic Industry Roundtable) criteria for rigorous stroke preclinical design include: randomisation and allocation concealment; blinded outcome assessment; inclusion of both sexes (male-only studies have repeatedly failed to translate due to sex-specific ischaemic tolerance via oestrogen/progesterone); age-matched animals (most stroke research uses 8-12 week animals, but clinical stroke is predominantly in patients >65 years); comorbidity inclusion (hypertension, diabetes); and reporting of physiological monitoring (CBF by laser Doppler during occlusion, PaCO₂, temperature). tMCAO (filament model, 60-90min) is the most widely used model but produces variable infarct volumes (CV ~30-40%) — researchers should power studies accordingly. Permanent MCA occlusion, photothrombosis, and embolic models each have distinct ischaemia architectures and should be matched to the specific translational question. Outcome endpoints: infarct volume (TTC or cresyl violet at 24-48h; MRI T2/DWI for longitudinal studies), neurological deficit battery (Longa, mNSS, adhesive removal, rotarod), and long-term cognitive assessment (Morris water maze, novel object recognition) for research applications studies.

William is a research analyst at Peptides Lab UK, specialising in research peptides, laboratory compounds, and sourcing standards for high-purity peptide products.

You May Also Like